title: Characterization and clinical course of patients not receiving aspirin for acute myocardial infarction: results from the MITRA and MIR studies.
abstract: BACKGROUND
  Clinical trials have shown the efficacy of aspirin for acute myocardial infarction (AMI). However, not all patients receive aspirin for AMI. The aim of this study was to provide information on characteristics and clinical course of patients not treated with aspirin for AMI.
  
  
  METHODS
  We analyzed the data of the Myocardial Infarction Registry (MIR) and the Maximal Individual Therapy of Acute Myocardial Infarction (MITRA) registry. MITRA and MIR were prospective multicenter registries of patients with ST segment elevation myocardial infarction in Germany.
  
  
  RESULTS
  Of 22,572 patients registered from 1994 to 1998, 1767 (7.8%) did not receive aspirin within the first 48 hours after admission. Multivariate analysis revealed two main factors associated with withholding aspirin for AMI: relative contraindications to aspirin (gastric ulcer [odds ratio (OR) 4.9, 95% confidence interval (CI) 3.7-5.7], renal insufficiency [OR 1.4, 95% CI 1.1-1.8]), and critical clinical state at admission (cardiogenic shock [OR 1.5, 95% CI 1.2-2.1] and prehospital resuscitation [OR 1.8, 95% CI 1.4-2.2]). In addition, these patients were significantly less likely to receive reperfusion therapy and adjunctive medical therapy such as beta-blockers and angiotensin-converting enzyme inhibitors. In-hospital mortality after adjustment for baseline characteristics was 27.2% in patients without aspirin compared with 11.1% in patients treated with aspirin.
  
  
  CONCLUSIONS
  Only a minority of AMI patients (7.8%) did not receive aspirin. Relative contraindications to aspirin and a critical clinical state at admission were the main factors associated with withholding aspirin for AMI. Even after adjustment for patient characteristics, the mortality of patients without aspirin was almost three times higher.
authors.affiliation: Hezzentrum Ludwigshafen, Department of Cardiology, Bremserstr. 79, 67063 Ludwigshafen, Germany. frillin@klilu.de
authors.forename: B
authors.initials: B
authors.lastname: Frilling
authors.forename: R
authors.initials: R
authors.lastname: Schiele
authors.forename: A K
authors.initials: AK
authors.lastname: Gitt
authors.forename: R
authors.initials: R
authors.lastname: Zahn
authors.forename: S
authors.initials: S
authors.lastname: Schneider
authors.forename: H G
authors.initials: HG
authors.lastname: Glunz
authors.forename: U
authors.initials: U
authors.lastname: Gieseler
authors.forename: B
authors.initials: B
authors.lastname: Baumgärtel
authors.forename: F
authors.initials: F
authors.lastname: Asbeck
authors.forename: J
authors.initials: J
authors.lastname: Senges
mesh_terms: D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D005260:Female; D005858:Germany / Q000453:epidemiology; D006760:Hospitalization / Q000706:statistics & numerical data; D006764:Hospitals, Community / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000453:epidemiology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011446:Prospective Studies; D012042:Registries / Q000706:statistics & numerical data*; D015996:Survival Rate
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin